Recursion Pharmaceuticals, Inc. (RXRX) stock forecast & analysis
4.63
NasdaqGS · USD
Down: -0.15, -3.1%
1 analysis
- Open
- 4.80
- Previous close
- 4.78
- Day range
- 4.40 – 5.19
- 52-week range
- 2.77 – 7.18
- Volume (shares)
- 71.05M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 535.34M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.03
- Market cap
- 2.48B
Market Scanner’s AI analysis of Recursion Pharmaceuticals, Inc. (RXRX), updated October 2026: RXRX's recent analyses covered a strong upward technical trend against a backdrop of significant year-over-year revenue decline and negative profitability metrics.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Recursion Pharmaceuticals, Inc. (RXRX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
RXRX's recent analyses covered a strong upward technical trend against a backdrop of significant year-over-year revenue decline and negative profitability metrics.
Recent analyses for RXRX examined a notable upward trend in its stock price, supported by several technical indicators including moving averages and the MACD. This was contrasted with the company's financial performance, which showed a substantial year-over-year decrease in quarterly revenue and persistent negative operating margins and returns on equity. News coverage provided limited specific insights into the company's recent performance.
RXRX news & sentiment
News headlines offered limited specific insights into RXRX's situation, with general mentions of stock activity and market trends lacking direct relevance. Social media discussion was not covered in the provided notes.
RXRX technical picture
RXRX's price action showed a strong upward trend, trading significantly above its 50-day and 200-day Simple Moving Averages. Momentum indicators, including the RSI and MFI, suggested strong buying pressure and approached overbought territory, while the MACD indicated bullish momentum.
Fundamentals
The company's recent financial performance showed a substantial year-over-year decrease in quarterly revenue. Profitability metrics, including operating margin and return on equity, were significantly negative, with trailing twelve months gross profit also negative.
Factors discussed — upside
- Stock price significantly above 50-day and 200-day Simple Moving Averages
- 10-day Exponential Moving Average below current price
- Relative Strength Index approaching overbought territory
- Money Flow Index in overbought territory indicating strong buying pressure
- Positive MACD value suggesting bullish momentum
Factors discussed — risks
- 60.1% year-over-year decrease in quarterly revenue
- TTM operating margin of -1008.6%
- TTM return on equity of -56.6%
- TTM gross profit was negative $392.6 million
- News headlines lacked specific details on stock movement or company performance
- Technical indicators
- Revenue trends
- Profitability metrics
- News sentiment
Summary updated .
RXRX technical indicators
Common technical indicators for RXRX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.49 | Price above |
| 10-day exponential moving average | 4.17 | Price above |
| Relative strength index (14-day) | 67.52 | Neutral |
| MACD line (12/26/9) | 0.2795 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 2.87 – 4.69 | Price inside the bands |
Analyses
Recent RXRX.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Recursion Pharmaceuticals, Inc.?
- The company's stock price has shown a strong upward trend, significantly surpassing key moving averages and supported by indicators suggesting substantial buying pressure and bullish momentum. Technical signals indicate the asset is approaching overbought territory but still exhibits room for growth within its current trend.
- What are the risks for Recursion Pharmaceuticals, Inc.?
- The company faces headwinds from a significant year-over-year decrease in quarterly revenue, coupled with deeply negative TTM operating margins and returns on equity. News coverage has also provided limited specific details regarding the company's recent performance or stock movements.
- Is Recursion Pharmaceuticals, Inc. bullish or bearish?
- Recent AI analyses of Recursion Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The company's stock price has shown a strong upward trend, significantly surpassing key moving averages and supported by indicators suggesting substantial buying pressure and bullish momentum. Technical signals indicate the asset is approaching overbought territory but still exhibits room for growth within its current trend. Discussed risks: The company faces headwinds from a significant year-over-year decrease in quarterly revenue, coupled with deeply negative TTM operating margins and returns on equity. News coverage has also provided limited specific details regarding the company's recent performance or stock movements. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Recursion Pharmaceuticals, Inc.?
- News headlines offered limited specific insights into RXRX's situation, with general mentions of stock activity and market trends lacking direct relevance. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Recursion Pharmaceuticals, Inc.?
- Every analysis of Recursion Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh RXRX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.